CureVac N.V. CVAC 深 滬
等待開盤 12-20 09:30:00 美东时间
4.16
-0.120
-2.80%
華盛通- 最 高4.19
- 今 開4.15
- 成交量 279.29万股
- 最 低 4.08
- 昨 收 4.28
- 總市值 9.36亿
- 52周最高 5.72
- 市盈率 靜 5.32
- 換手率 1.24%
- 52周最低 2.475
- 委 比 25.33%
- 總股本 2.25亿
- 歷史最高 151.80
- 量 比 2.08
- 振 幅 2.57%
- 歷史最低 2.215
- 每 手 1
- 風險率 1.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
BioNTech完成对CureVac的收购，收购比例达86.75%，剩余股份将于2026年1月通过强制收购完成。此次收购将增强BioNTech在mRNA设计、递送配方和生产方面的能力。CureVac将继续运营，BioNTech将进行战略分析以确定未来架构。
12-18 09:45
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
BioNTech announced that the minimum condition for its exchange offer of CureVac shares has been met, with approximately 81.74% of CureVac's outstanding shares tendered. The subsequent offering period has begun and will expire on December 18, 2025. BioNTech will now deliver ADSs or cash to tendering CureVac shareholders, completing the transaction. Non-tendering holders will receive ADSs through the post-offer reorganization, subject to a 15% Dutc...
12-03 14:01
CureVac Shareholders Approve BioNTech Exchange Offer
CureVac ( ($CVAC) ) just unveiled an announcement. On November 25, 2025, CureVa...
11-26 23:27
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
BioNTech announced the approval of its exchange offer for all outstanding shares of CureVac at an extraordinary general meeting held on November 25, 2025. Over 99.16% of CureVac shareholders voted in favor of the proposals. The offer is set to expire at 9:00 am Eastern Time on December 3, 2025, with shareholders advised to tender their shares by 6:00 pm Eastern Time on December 2, 2025. The exchange ratio is 0.05363 of a BioNTech ADS per CureVac ...
11-26 12:30
CureVac Q3 EPS $1.41 Beats $(0.17) Estimate, Sales $63.295M Beat $14.520M Estimate
CureVac (NASDAQ:CVAC) reported quarterly earnings of $1.41 per share which beat the analyst consensus estimate of $(0.17) by 929.41 percent. This is a 687.5 percent increase over losses of $(0.24) per share from the same
11-24 21:18
CureVac GAAP EPS of €1.21, revenue of €54.13M
CureVac BV press release (CVAC): Q3 GAAP EPS of €1.21. Revenue of €54.13M (-89.0% Y/Y). Strong cash and cash equivalents position of €416.1 million as of September 30, 2025, confirming expected cash r...
11-24 20:46
BioNTech Commences Public Exchange Offer For All Outstanding Shares Of CureVac; CureVac Shareholders Receive ~$5.46 In BioNTech ADSs For Each CureVac Share
Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next milestone in the execution of its oncology
10-22 18:51
BioNTech杀疯了
（来源：药剂Talks） mRNA疫苗巨头BioNTech正在狂奔。 6月2日，百时美施贵宝（BMS）宣布就PD-L1/VEGF双抗BNT327（普米斯生物的...
09-12 09:15
BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data
BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China.
09-05 21:09
Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Cassava Sciences, Inc. announced that its CEO, Rick Barry, will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York City on September 8, 2025. The event will feature a corporate presentation at 5 PM ET, available via webcast and replay on Cassava's investor website for 90 days. Cassava, a biotechnology company focused on CNS disorder treatments, is based in Austin, Texas.
08-25 12:00
